Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction
Spanish National Centre for Cardiovascular Research · Centro de Investigación Biomédica en Red · +70 more institutions
Abstract
Current guideline recommendations for the use of beta-blockers after myocardial infarction without reduced ejection fraction are based on trials conducted before routine reperfusion, invasive care, complete revascularization, and contemporary pharmacologic therapies became standard practice.
We conducted an open-label, randomized trial in Spain and Italy to evaluate the effect of beta-blocker therapy, as compared with no beta-blocker therapy, in patients with acute myocardial infarction (with or without ST-segment elevation) and a left ventricular ejection fraction above 40%. The primary outcome was a composite of death from any cause, reinfarction, or hospitalization for heart failure.
Citation impact
- FWCI
- 92.92
- Percentile
- 100%
- References
- 24
Authors
64- BIBorja IbáñezCorresponding
Spanish National Centre for Cardiovascular Research, Centro de Investigación Biomédica en Red, Hospital Universitario Fundación Jiménez Díaz, Universidad Autónoma de Madrid
- RLRoberto Latini
Mario Negri Institute for Pharmacological Research
- XRXavier Rosselló
Spanish National Centre for Cardiovascular Research, Centro de Investigación Biomédica en Red, Health Research Institute of the Balearic Islands, Hospital Universitario Son Espases
- ADAlberto Domínguez‐Rodríguez
Universidad de La Laguna, Hospital Universitario de Canarias, Centro de Investigación Biomédica en Red, Fundación Canaria de Investigación Sanitaria
- FFFelipe Fernández‐Vázquez
Hospital de León
Topics & keywords
- BETA (programming language)
- Ejection fraction
- Cardiology
- Myocardial infarction
- Internal medicine
- Fraction (chemistry)
- Medicine
- Chemistry